The estimated Net Worth of Jeffrey Arvin Fink is at least $25.7 Thousand dollars as of 16 December 2020. Mr. Fink owns over 5,625 units of Lipocine Inc stock worth over $25,723 and over the last 11 years he sold LPCN stock worth over $0. In addition, he makes $0 as Director at Lipocine Inc.
Jeffrey has made over 2 trades of the Lipocine Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 5,625 units of LPCN stock worth $22,050 on 16 December 2020.
The largest trade he's ever made was exercising 5,625 units of Lipocine Inc stock on 16 December 2020 worth over $22,050. On average, Jeffrey trades about 577 units every 83 days since 2014. As of 16 December 2020 he still owns at least 6,562 units of Lipocine Inc stock.
You can see the complete history of Mr. Fink stock trades at the bottom of the page.
Jeffrey A. Fink is Director of the Lipocine Inc. Mr. Fink has over 20 years of finance and strategy experience within the life science and healthcare industry. Mr. Fink is currently the managing director of Gambel Oaks Advisors, LLC, a strategic and financial advisory firm dedicated to the life sciences and allied industries. Mr. Fink spent over twenty years in the investment banking industry advising life science clients in the U.S. and Europe on the full range of financing and strategic advisory assignments. He was head of Healthcare Investment Banking for Robert W. Baird & Co. in Chicago until 2007, and prior to that was a partner in the Healthcare Group at Dresdner Kleinwort Wasserstein (the successor firm to Wasserstein Perella) and head of Mergers and Acquisitions for Prudential Vector Healthcare Securities International, Inc., a dedicated biotechnology and life sciences investment bank. Mr. Fink’s advisory clients have included Schering AG, Genentech, Boehringer Ingleheim, F. Hoffman LaRoche, Ltd., the Ares Serrono Group and Celgene Pharmaceuticals. Mr. Fink has been involved in over fifty public and private equity financings, and he has advised on over $3 billion in mergers, acquisitions and strategic alliances. Mr. Fink also serves on the Boards of Navigen, Inc. and Metalosensors. Mr. Fink has an MBA in finance and accounting from the University of Michigan and a BA in economics and business administration from Kalamazoo College.
Jeffrey Fink is 57, he's been the Director of Lipocine Inc since 2014. There are 5 older and 7 younger executives at Lipocine Inc. The oldest executive at Lipocine Inc is Dr. Mahesh V. Patel Ph.D., 64, who is the Co-Founder, Interim Principal Financial Officer, Chairman, Pres & CEO.
Jeffrey's mailing address filed with the SEC is 675 Arapeen Dr #202, Salt Lake City, UT 84108, USA.
Over the last 11 years, insiders at Lipocine Inc have traded over $9,045 worth of Lipocine Inc stock and bought 890,945 units worth $696,169 . The most active insiders traders include Mahesh V. Patel, John W. Higuchi, and Morgan R Brown. On average, Lipocine Inc executives and independent directors trade stock every 72 days with the average trade being worth of $148,846. The most recent stock trade was executed by Mahesh V. Patel on 25 May 2023, trading 8,706 units of LPCN stock currently worth $43,791.
lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.
Lipocine Inc executives and other stock owners filed with the SEC include: